People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The regulator's letter warns of new scrutiny on Ergen's EchoStar and considers opening satellite spectrum to rivals including SpaceX. The move is a sign of increased investor excitement about AI's ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...